Somewhat Positive News Coverage Somewhat Unlikely to Impact Viveve Medical (VIVE) Stock Price
News stories about Viveve Medical (NASDAQ:VIVE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viveve Medical earned a news impact score of 0.04 on Accern’s scale. Accern also gave media coverage about the company an impact score of 43.9528408047808 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- BRIEF-Viveve Announces Pricing Of Public Offering Of Shares (reuters.com)
- Pre-Open Movers 02/08: (TWTR) (INFN) (GRUB) Higher; (IRBT) (GEMP) (IPHI) Lower (more…) (streetinsider.com)
- VIVE: SUI Indication Could Further Enhance Marketing Message, Drive Adoption (finance.yahoo.com)
- Mizuho Reiterates “Buy” Rating for Viveve Medical (VIVE) (americanbankingnews.com)
- Viveve Announces Proposed Public Offering of Shares of Common Stock (finance.yahoo.com)
Shares of Viveve Medical (VIVE) traded down $0.08 during midday trading on Thursday, reaching $3.75. 2,835,904 shares of the company traded hands, compared to its average volume of 261,793. The company has a market capitalization of $77.51, a price-to-earnings ratio of -1.74 and a beta of -0.79. Viveve Medical has a fifty-two week low of $3.30 and a fifty-two week high of $11.16. The company has a debt-to-equity ratio of 2.72, a quick ratio of 3.63 and a current ratio of 3.89.
A number of equities research analysts have recently commented on the stock. Mizuho assumed coverage on shares of Viveve Medical in a research note on Thursday, November 16th. They issued a “buy” rating and a $10.00 price objective on the stock. Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a “buy” rating in a research note on Monday, October 23rd. Northland Securities assumed coverage on shares of Viveve Medical in a research note on Friday, January 5th. They issued an “outperform” rating and a $8.00 price objective on the stock. ValuEngine raised shares of Viveve Medical from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating on shares of Viveve Medical in a research note on Thursday, January 4th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Viveve Medical currently has a consensus rating of “Buy” and an average price target of $10.00.
COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/02/08/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-viveve-medical-vive-stock-price.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.